ANNX Stock Price, Annexon, Inc. Quote, Chart

Market Summary

USD4.33-0.03

Market Closed

-0.69%

ANNX Alerts

1 major insider buys recently.

ANNX Stock Price

View Fullscreen

ANNX RSI Chart

ANNX Valuation

Market Cap

339.3M

Price/Earnings (Trailing)

-2.81

EV/EBITDA

-2.22

Price/Free Cashflow

-2.91

MarketCap/EBT

-3.62

ANNX Price/Sales (Trailing)

ANNX Profitability

Return on Equity

-46.01%

Return on Assets

-39.71%

Free Cashflow Yield

-34.36%

ANNX Fundamentals

ANNX Earnings

Earnings (TTM)

-120.7M

Earnings Growth (Yr)

34.91%

Earnings Growth (Qtr)

9.73%

Breaking Down ANNX Revenue

Last 7 days

-8.8%

Last 30 days

-5.7%

Last 90 days

-15.6%

Trailing 12 Months

-25.3%

How does ANNX drawdown profile look like?

ANNX Financial Health

Current Ratio

20.62

ANNX Investor Care

Shares Dilution (1Y)

64.22%

Diluted EPS (TTM)

-1.46

Tracking the Latest Insider Buys and Sells of Annexon, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	carson william h.	bought	14,982	4.682	3,200	-
Apr 08, 2024	carson william h.	bought	19,411	6.066	3,200	-
Feb 20, 2024	lew jennifer	sold	-14,339	5.53	-2,593	evp & chief financial officer
Feb 20, 2024	yednock ted	sold	-14,348	5.51	-2,604	evp & chief innovation officer
Feb 20, 2024	overdorf michael	sold	-10,691	5.48	-1,951	evp & chief business officer
Feb 16, 2024	overdorf michael	acquired	-	-	39,000	evp & chief business officer
Feb 16, 2024	lew jennifer	acquired	-	-	39,000	evp & chief financial officer
Feb 16, 2024	dananberg jamie	acquired	-	-	39,000	chief medical officer
Feb 16, 2024	yednock ted	acquired	-	-	39,000	evp & chief innovation officer
Feb 16, 2024	artis dean richard	acquired	-	-	39,000	evp & chief scientific officer

Which funds bought or sold ANNX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-9.82	14,466	48,570	-%
May 16, 2024	COMERICA BANK	new	-	71,700	71,700	-%
May 16, 2024	JANE STREET GROUP, LLC	added	318	805,823	949,487	-%
May 15, 2024	Atom Investors LP	sold off	-100	-70,892	-	-%
May 15, 2024	SILVERARC CAPITAL MANAGEMENT, LLC	sold off	-100	-1,895,130	-	-%
May 15, 2024	Soleus Capital Management, L.P.	reduced	-43.27	-243,408	2,096,510	0.16%
May 15, 2024	Bellevue Group AG	new	-	15,647,000	15,647,000	0.24%
May 15, 2024	Walleye Capital LLC	sold off	-100	-1,717,390	-	-%
May 15, 2024	Forefront Analytics, LLC	reduced	-52.63	-35,768	106,245	0.05%
May 15, 2024	Bain Capital Life Sciences Investors, LLC	added	7.96	25,802,200	62,402,400	5.02%

Are Funds Buying or Selling ANNX?

Are funds buying ANNX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ANNX

No. of Funds

ANNX Alerts

1 major insider buys recently.

Unveiling Annexon, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 22, 2024	bb biotech ag	5.2%	4,682,290	SC 13G
Feb 14, 2024	venrock healthcare capital partners ii, l.p.	0.0%	0	SC 13G/A
Feb 14, 2024	fairmount funds management llc	0.4%	322,893	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	4.7%	3,673,570	SC 13G/A
Feb 14, 2024	eventide asset management, llc	0.0%	0	SC 13G/A
Feb 14, 2024	redmile group, llc	9.9%	8,083,776	SC 13G/A
Feb 14, 2024	citadel advisors llc	1.3%	6	SC 13G/A
Feb 13, 2024	bain capital life sciences fund, l.p.	9.99%	8,061,719	SC 13G/A
Feb 13, 2024	logos global management lp	8.3%	6,944,444	SC 13G/A
Feb 12, 2024	point72 asset management, l.p.	6.2%	4,856,400	SC 13G

Recent SEC filings of Annexon, Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 07, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 22, 2024	SC 13G	Major Ownership Report
Apr 10, 2024	4	Insider Trading
Apr 05, 2024	424B5	Prospectus Filed

Peers (Alternatives to Annexon, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Annexon, Inc. News

Latest updates

Annexon, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	2.1%	304	298	204	233	269	285	313	221	251	287	310	332	333	356	376	131	50.00
Current Assets	2.6%	271	264	169	198	233	248	275	181	211	248	275	304	331	354	374	126	45.00
Cash Equivalents	-32.0%	153	225	133	114	144	140	212	106	114	76.00	70.00	101	208	269	371	125	44.00
Net PPE	-3.6%	14.00	15.00	15.00	16.00	16.00	17.00	17.00	17.00	18.00	18.00	12.00	5.00	1.00	2.00	2.00	2.00	2.00
Liabilities	-11.6%	42.00	47.00	47.00	48.00	54.00	54.00	52.00	53.00	50.00	55.00	46.00	36.00	12.00	12.00	10.00	14.00	6.00
Current Liabilities	-26.7%	13.00	18.00	17.00	18.00	23.00	22.00	20.00	20.00	17.00	22.00	12.00	10.00	11.00	11.00	9.00	13.00	5.00
Shareholder's Equity	4.7%	262	251	157	185	215	231	261	168	201	232	264	295	321	344	365	-	-
Retained Earnings	-4.4%	-597	-572	-544	-512	-476	-438	-403	-368	-331	-296	-258	-223	-192	-165	-142	-127	-102
Additional Paid-In Capital	4.5%	860	823	702	697	692	670	665	537	533	528	523	519	514	510	508	9.00	2.00
Accumulated Depreciation	10.7%	6.00	5.00	-	-	-	3.00	-	-	-	-	-	3.00	3.00	2.00	2.00	2.00	1.00
Shares Outstanding	-100.0%	-	78.00	75.00	75.00	74.00	48.00	69.00	39.00	39.00	39.00	38.00	38.00	38.00	38.00	28.00	-	-
Float	-	-	-	-	121	-	-	-	125	-	-	-	750	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	-20.4%	-28,267	-23,477	-28,291	-36,381	-32,993	-27,139	-30,718	-28,164	-30,288	-28,321	-29,715	-24,634	-23,440	-19,256	-13,584	-10,246	-10,001	-	-	-
Share Based Compensation	6.7%	4,660	4,367	4,549	4,660	4,607	4,833	4,911	4,520	4,252	4,355	4,428	4,517	2,962	1,991	1,471	763	663	-	-	-
Cashflow From Investing	-3441.1%	-77,302	-2,183	47,838	5,531	19,517	-43,615	14,098	19,709	68,251	33,697	-1,278	-83,074	-37,581	-82,872	-276	-	-	-	-	-
Cashflow From Financing	-72.4%	32,412	117,598	-	345	17,581	108	122,668	113	19.00	948	-73.00	652	268	-	259,781	101,666	-571	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ANNX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 20,963	$ 32,345
General and administrative	7,609	8,897
Total operating expenses	28,572	41,242
Loss from operations	(28,572)	(41,242)
Interest and other income, net	3,396	2,566
Net loss	$ (25,176)	$ (38,676)
Net loss per share, basic	$ (0.21)	$ (0.52)
Net loss per share, diluted	$ (0.21)	$ (0.52)
Weighted-average shares used in computing net loss per share, basic	122,673,202	73,855,642
Weighted-average shares used in computing net loss per share, diluted	122,673,202	73,855,642

ANNX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 151,941	$ 225,110
Short-term investments	113,007	34,606
Prepaid expenses and other current assets	5,792	4,144
Total current assets	270,740	263,860
Restricted cash	1,032	1,032
Property and equipment, net	14,235	14,773
Operating lease right-of-use assets	17,701	18,009
Other non-current assets	361
Total assets	304,069	297,674
Current liabilities:
Accounts payable	3,972	5,487
Accrued liabilities	6,857	10,235
Operating lease liabilities, current	2,254	2,165
Other current liabilities	50	41
Total current liabilities	13,133	17,928
Operating lease liabilities, non-current	28,531	29,190
Total liabilities	41,664	47,118
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock	90	78
Additional paid-in capital	860,092	823,029
Accumulated other comprehensive loss	(102)	(52)
Accumulated deficit	(597,675)	(572,499)
Total stockholders’ equity	262,405	250,556
Total liabilities and stockholders’ equity	$ 304,069	$ 297,674

About Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barrÃƒÂ© syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

CEO	Mr. Douglas Love Esq., J.D.
WEBSITE	annexonbio.com
INDUSTRY	Biotechnology
EMPLOYEES	77

Annexon, Inc. Frequently Asked Questions

What is the ticker symbol for Annexon, Inc.? What does ANNX stand for in stocks?

ANNX is the stock ticker symbol of Annexon, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Annexon, Inc. (ANNX)?

As of Fri May 17 2024, market cap of Annexon, Inc. is 339.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANNX stock?

You can check ANNX's fair value in chart for subscribers.

What is the fair value of ANNX stock?

You can check ANNX's fair value in chart for subscribers. The fair value of Annexon, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Annexon, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANNX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Annexon, Inc. a good stock to buy?

The fair value guage provides a quick view whether ANNX is over valued or under valued. Whether Annexon, Inc. is cheap or expensive depends on the assumptions which impact Annexon, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANNX.